1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 43,400 | 43,600 | 13:03 | |
| 43,200 | 44,400 | 10.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.04. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 2 | GlobeNewswire (USA) | ||
| 18.03. | Stifel raises Spyre stock price target to $92 on TL1A potential | 1 | Investing.com | ||
| 16.03. | Leerink reiterates Spyre stock Outperform on faster trial timeline | 2 | Investing.com | ||
| 16.03. | Guggenheim: Spyre Therapeutics bleibt Top-Pick für 2026 | 3 | Investing.com Deutsch | ||
| 16.03. | Spyre Therapeutics stock remains top 2026 pick at Guggenheim | 1 | Investing.com | ||
| 06.03. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| 19.02. | Earnings Summary: Spyre Therapeutics Q4 | 2 | Benzinga.com | ||
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.02. | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 210 | GlobeNewswire (Europe) | On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second... ► Artikel lesen | |
| 19.02. | Spyre Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.02. | Spyre Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 16.02. | Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026 | 3 | Insider Monkey | ||
| 06.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 3 | GlobeNewswire (USA) | ||
| 06.02. | Spyre Therapeutics appoints Kate Tansey Chevlen as Chief Commercial Officer | 2 | PMLiVE | ||
| 23.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| 15.01. | Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating | 3 | Insider Monkey | ||
| 12.01. | Spyre Therapeutics accelerates clinical trial timeline for IBD treatments | 2 | Investing.com | ||
| 12.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 | 234 | GlobeNewswire (Europe) | "6 in '26" expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete... ► Artikel lesen | |
| 12.01. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 50,50 | -0,98 % | Stifel reiterates Oruka Therapeutics stock rating ahead of trial data | ||
| PALVELLA THERAPEUTICS | 110,00 | +0,92 % | Palvella Therapeutics Inc.: Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales | Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S.... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 76,00 | -1,30 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| LENZ THERAPEUTICS | 9,050 | -2,58 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Launched VIZZ- (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for... ► Artikel lesen | |
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 23,050 | +0,48 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,480 | -3,16 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,360 | -5,54 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCELLX | 114,83 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen |
SPYRE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,91 % bei einem Aktienkurs von 44,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.